Involving Nonmembrane Bound Receptor Binding Or Protein Binding Other Than Antigen-antibody Binding Patents (Class 435/7.8)
-
Patent number: 7927812Abstract: The present invention relates to a method for diagnosing an advanced ischemic coronary heart disease comprising the steps of determining an amount of a cardiac troponin in a sample of a subject and diagnosing the disease by comparing the amount determined with a reference amount of the cardiac troponin.Type: GrantFiled: August 13, 2007Date of Patent: April 19, 2011Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Hess, Andrea Hess
-
Patent number: 7927813Abstract: The invention relates to a method of screening and identifying modulators of the protein interaction between new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.Type: GrantFiled: January 31, 2006Date of Patent: April 19, 2011Assignees: Les Laboratories Servier, HybrigenicsInventors: Olivier Geneste, John Hickman, Jean-Christophe Rain
-
Patent number: 7927827Abstract: A system for the detection of ligands comprising at least one receptor and an amplification mechanism coupled to the receptor wherein an amplified signal is produced as a result of receptor binding a ligand. Examples of suitable amplification mechanisms include antibody-embedded liquid crystalline materials; use of alpha-2-macroglobulin to encage an enzyme, whereby the enzyme is separated from its substrate by an receptor; and a receptor engineered to inhibit the active of site of an enzyme only in the absence of a ligand. Also provided are methods for the automatic detection of ligands.Type: GrantFiled: May 21, 2007Date of Patent: April 19, 2011Assignee: Kent State UniversityInventors: Gary D. Niehaus, Christopher J. Woolverton, Kathleen J. Doane, Steven P. Schmidt, Steven A. Signs
-
Patent number: 7928215Abstract: The present inventors succeeded in isolating GWT1 (PfGWT1), which is one of the enzymes involved in GPI biosynthesis in the malaria parasite P. falciparum. In addition, the inventors revealed that degenerate mutant DNAs, with a lower AT content than the DNA encoding the PfGWT1 protein, can complement the phenotype of GWT1-deficient yeast. Based on the findings, the present invention provides the GWT1 protein of malaria parasites and the use of the protein in methods of screening for antimalarial drugs. The present invention also provides degenerate mutant DNAs encoding proteins involved in GPI biosynthesis, and which have a lower AT content than the original DNAs. The present invention also provides methods of screening for antimalarial drugs which use the degenerate mutant DNAs.Type: GrantFiled: November 21, 2003Date of Patent: April 19, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Katsura Hata, Kaoru Ogawa, Itaru Tsukada, Kazutaka Nakamoto, Koji Sagane, Keigo Tanaka, Kappei Tsukahara, Toshihiro Horii
-
Patent number: 7923216Abstract: A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.Type: GrantFiled: September 16, 2003Date of Patent: April 12, 2011Assignees: Institut Pasteur, Centre Nationale de la Recherche ScientifiqueInventors: Sylvie Roux, Philippe Brulet, Cécile Saint Cloment, Julien Barbier, Jordi Molgo
-
Publication number: 20110081348Abstract: Method of identifying an anti-fungal agent which targets as an essential protein or gene of a fungus comprising contacting a candidate substance with (i) a protein which comprises the sequence shown by SEQ ID NOS: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 50, 53, 56, 59, 61 or 63, or (ii) a protein which has 60% identity with (i), or (iii) a protein comprising a fragment of (i) or (ii) which fragment has a length of at least 50 amino acids, or (iv) a polynucleotide that comprises a sequence which encodes (i), (ii) or (iii), or (v) a polynucleotide comprising a sequence which has at least 70% identity with the coding sequence of (iv), and determining whether the candidate substance binds or modulates (i), (ii), (iii), (iv), or (v), wherein binding or modulation of (i), (ii), (iii), (iv), or (v) indicates that the candidate substance is an anti-fungal agent.Type: ApplicationFiled: December 1, 2005Publication date: April 7, 2011Inventors: Nina Brogden, Michael John Bromley, Paul David Carr, Sarah Jane Kaye, Jason David Oliver, Daniel Scott Tuckwell
-
Patent number: 7919262Abstract: The present disclosure is directed to methods for treatment and prevention of disease states characterized by a decreased 14-3-3 polypeptide expression or activity. In one embodiment, the present disclosure provides methods for the treatment and/or prevention of Parkinson's disease, neurodegeneration and/or diseases characterized, at least in part, by neurodegeneration, by increasing a 14-3-3 polypeptide activity.Type: GrantFiled: November 7, 2008Date of Patent: April 5, 2011Assignee: The UAB Research FoundationInventors: Talene Alene Yacoubian, David G. Standaert
-
Publication number: 20110070597Abstract: A thin-film passive sampler for use in detecting hydrophobic organic contaminants in air or aqueous environments. The sampler features a relatively thin layer of a suitable absorbent matrix coated directly on a solid support unit made of an inert material such as titanium or glass fibers. The passive samplers are simple and cost-effective to manufacture, easy to use, and exhibit rapid equilibration times and high accuracy.Type: ApplicationFiled: May 20, 2010Publication date: March 24, 2011Applicant: UNIVERSITY OF CONNECTICUTInventors: Penny Vlahos, Tom Harner
-
Publication number: 20110071178Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.Type: ApplicationFiled: April 16, 2010Publication date: March 24, 2011Applicant: Northeastern UniversityInventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
-
Publication number: 20110070596Abstract: Agents and methods for qualitative and quantitative analysis a protein complex or protein complexes using isotope-labeled symmetrical bifunctional crosslinkers and mass spectrometry are provided. Targeting moieties, cell permeability moieties, or affinity moieties, may be appended to the bifunctional crosslinkers. The isotope-labeled symmetrical bifunctional crosslinkers may be used in a kit or as a library.Type: ApplicationFiled: February 15, 2010Publication date: March 24, 2011Applicant: GENERAL ELECTRIC COMPANYInventors: Nichole Lea Wood, Mohan Mark Amaratunga, Hans Grade, Faisal Ahmed Syud, Anup Sood, Reginald Donovan Smith, Ayse Betul Dinc, Amy Casey Williams, Anthony John Murray, Gregory Daryll Goddard
-
Patent number: 7910320Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.Type: GrantFiled: August 13, 2008Date of Patent: March 22, 2011Assignee: Galapagos N.V.Inventors: Pascal Gerard Merchiers, Marcel Hoffman, Koenraad Frederik Florentina Spittaels
-
Patent number: 7910698Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.Type: GrantFiled: February 22, 2007Date of Patent: March 22, 2011Assignee: Schering CorporationInventors: Scott Altmann, Xiaorui Yao, Kim Ann O'Neill, Brian E. Hawes
-
Publication number: 20110065128Abstract: As described herein, signaling events occurring in neurons or at neuronal synapses have been identified that involve Cdk5 and various other molecules which bind to, are activated by, and/or activate Cdk5. Of particular relevance are interactions that stimulate calpain cleavage of p35 into p25, which binds Cdk5 in pathologic states. Assays to identify modulators of these interactions are provided.Type: ApplicationFiled: October 4, 2010Publication date: March 17, 2011Inventors: James A. Bibb, Ammar H. Hawasli
-
Patent number: 7901874Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 9, 2004Date of Patent: March 8, 2011Assignees: Hubit Genomix, Inc., Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe
-
Publication number: 20110045474Abstract: The invention provides diagnostic, prognostic, and therapeutic uses for detecting COP1 overexpression in a variety of cancers. The methods and uses can further include detecting p53 expression. The invention also provides reagents and kits for use in screening for test compounds that interfere with COP1 and p53 binding.Type: ApplicationFiled: June 29, 2010Publication date: February 24, 2011Inventors: David Dornan, Dorothy French, Vishva Dixit
-
Publication number: 20110045495Abstract: The present invention relates to a method for detection of a renal cancer, comprising measuring any one of or a plurality of polypeptides shown in SEQ ID NOS: 1-7, mutants thereof, or fragments thereof in a biological sample from a subject, and to a composition for diagnosis or detection of the renal cancer.Type: ApplicationFiled: January 16, 2009Publication date: February 24, 2011Inventors: Yoshinori Tanaka, Michimoto Kobayashi, Shiori Tomoda, Giman Jung, Osamu Ogawa, Eijiro Nakamura
-
Patent number: 7892755Abstract: The present invention provides a method of screening a compound or its salt that alters binding properties of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and a ligand capable of specifically binding to the protein or its salt, which comprises using (a) the protein, its partial peptide, or a salt thereof and (b) the ligand; a screening kit therefor, and so on. The screening method and kit of the present invention are useful for screening an agent for the prevention/treatment of, e.g., digestive tract disorders, cancer, immune disorders, type II diabetes mellitus or obesity, etc.Type: GrantFiled: August 29, 2005Date of Patent: February 22, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuaki Ito, Kazunori Nishi, Shoichi Ohkubo, Masataka Harada
-
Patent number: 7893205Abstract: A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis.Type: GrantFiled: September 5, 2008Date of Patent: February 22, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masatsugu Maeda, Noriko Yaguchi
-
Patent number: 7892772Abstract: Members of the IpaH superfamily constitute a novel class of E3 ubiquitin ligases which are useful for engineering products which modulate trafficking and destruction of target proteins inside a cell and useful targets for identifying new antimicrobial molecules which modulate, especially inhibit, E3 ligases.Type: GrantFiled: March 12, 2007Date of Patent: February 22, 2011Assignee: ITI Scotland LimitedInventors: John Roy Rohde, Claude Rene Raoul Parsot, Philippe Joseph Sansonetti
-
Publication number: 20110039718Abstract: The present invention relates to immobilization compounds and methods useful for the identification of JAK interacting compounds or for the purification or identification of JAK.Type: ApplicationFiled: November 11, 2008Publication date: February 17, 2011Applicant: CELLZOME AGInventor: Carsten Hopf
-
Patent number: 7888056Abstract: The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.Type: GrantFiled: June 26, 2008Date of Patent: February 15, 2011Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Darrell C. Conklin
-
Publication number: 20110033873Abstract: The present invention relates to proteomic markers for early detection of hepatocellular carcinoma, compositions for detecting changes of these proteomic markers, kits for detection of hepatocellular carcinoma, methods for detecting proteomic markers including these compositions, methods for screening drugs for hepatocellular carcinoma using these proteomic markers, and antibodies specific for these proteomic markers.Type: ApplicationFiled: March 12, 2009Publication date: February 10, 2011Inventors: Jin Young Park, Seok Joo Hong, Jongmin Kim, Youngtack Shim
-
Publication number: 20110033844Abstract: The invention provides a human PRCP which is associated with the cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of PRCP as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: May 25, 2007Publication date: February 10, 2011Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Brüggemeier, Adreas Geerts
-
Publication number: 20110021546Abstract: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.Type: ApplicationFiled: September 28, 2010Publication date: January 27, 2011Applicant: CELL SIGNALING TECHNOLOGY, INC.Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
-
Publication number: 20110020842Abstract: Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein.Type: ApplicationFiled: July 15, 2010Publication date: January 27, 2011Inventors: Alexey G. Ryazanov, Benjamin E. Turk
-
Publication number: 20110016590Abstract: The invention provides methods of identifying herbicidal auxins. The invention further provides auxin-herbicide-resistant plants and genes conferring auxin-herbicide resistance. This invention also provides a method of identifying other proteins that bind picolinate auxins from additional plant species. The invention further provides a method to identify the molecular binding site for picolinate auxins. The invention also includes the use of the picolinate herbicidal auxin target site proteins, and methods of discovering new compounds with herbicidal or plant growth regulatory activity. The invention also includes methods for producing plants that are resistant to picolinate herbicidal auxins. Specific examples of novel proteins associated with herbicide binding include AFB5, AFB4, and SGT1b.Type: ApplicationFiled: September 3, 2010Publication date: January 20, 2011Inventors: Terence A. Walsh, Glenn Hicks, Mary Honma, John P. Davies
-
Publication number: 20110008800Abstract: The present invention related to a method for crystallizing a CMY-10 being a ?-lactamase with extended-substrate spectrum, a crystal of CMY-10, and a crystal structure of CMY-10. With utilization of three-dimensional structure of CMY-10 protein provided by the present invention, it is possible to develop novel antibiotics or inhibitors that can prevent an emergence of resistance bacteria appeared by plasmatic class C ?-lactamases having extended-substrate specificity.Type: ApplicationFiled: January 28, 2010Publication date: January 13, 2011Applicants: Myongji University Industry and Academia CooperationInventors: Sang-Hee Lee, Sun-Shin Cha, Jung-Hun Lee, Ha-Il Jung
-
Publication number: 20110008292Abstract: Fructooligosaccharide (FOS)-related protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, FOS-related fusion proteins, antigenic peptides, and anti-FOS-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into which the expression vectors have been introduced. Methods for producing the polypeptides of the invention and methods for their use are further disclosed.Type: ApplicationFiled: September 23, 2010Publication date: January 13, 2011Applicant: North Carolina State UniversityInventors: Rodolphe Barrangou, Todd R. Klaenhammer, Eric Altermann
-
Patent number: 7862993Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 9, 2004Date of Patent: January 4, 2011Assignees: Hubit Genomix, Inc., Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe
-
Publication number: 20100323957Abstract: The invention provides methods and compositions for screening for modulators of EGFR activity. In particular, an assay for such modulators is provided, which includes methods of screening for modulators using models of the three dimensional structure of EGFR kinase domains.Type: ApplicationFiled: November 19, 2008Publication date: December 23, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA THE OFFICE OF THE PRESIDENTInventors: John Kuriyan, Xuewu Zhang, Natalia Jura
-
Publication number: 20100317536Abstract: A crystal comprising the collagen binding domain of human GPVI is provided and defined by structural atomic coordinates. Employing computer modeling based on the crystal structure, including methods for identifying inhibitors of GPVI collagen binding activity, methods for screening libraries of compounds for potential to bind to the GPVI collagen binding domain, and methods of identifying a compound useful for the treatment of a GPVI-mediated disorder, are also provided.Type: ApplicationFiled: March 28, 2007Publication date: December 16, 2010Applicant: University of CincinnatiInventors: Andrew B. Herr, Katsunori Horii
-
Patent number: 7851228Abstract: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.Type: GrantFiled: March 30, 2007Date of Patent: December 14, 2010Assignee: The Regents of the University of CaliforniaInventors: Nazneen Dewji, S. Jonathan Singer
-
Publication number: 20100312139Abstract: Disclosed are methods of diagnosing, screening and treating individuals at risk of elevated intracranial pressure based on detecting a transient decrease in serum ceruloplasmin and/or serum copper levels in the individual soon after occurrence of a head injury. This early drop in ceruloplasmin or copper level indicates an impending, potentially life threatening, elevation in the individual's intracranial pressure. Also disclosed are diagnostic applications and processes for identifying and producing diagnostic and prognostic assays useful for predicting elevated intracranial pressure, and test kits for performing such tests.Type: ApplicationFiled: June 4, 2010Publication date: December 9, 2010Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Pramod K. DASH, John B. REDELL, Georgene Hergenroeder, Anthony N. MOORE
-
Publication number: 20100311072Abstract: The subject matter disclosed and claimed herein concerns measuring the binding affinity of glucokinase (“GK”) using a fluorescence polarization (“FP”) assay. The FP method includes use of modified GK ligands bound to a fluorescent label. Binding affinity is determined by measuring displacement of fluorescent ligand by the known or suspected GK ligands. The subject matter disclosed and claimed herein provides a robust high-throughput FP assay for the determination of binding affinity of ligands to glucokinase. The FP binding assay displayed both glucose and nucleotide dependence, and a useful dynamic range. The binding IC50 data correlated well with GK activation EC50 data.Type: ApplicationFiled: January 28, 2009Publication date: December 9, 2010Inventors: Ramakrishna Seethala, Jessica Leihwa Dong, Kevin M. O'Malley
-
Publication number: 20100311807Abstract: The invention relates to inhibition of Par-1b kinase activity for treating disorders including diabetes and obesity. The invention also relates to screening for compounds or compositions that inhibit the kinase activity of Par-1b protein, which compounds and compositions are useful in the treatment of diabetes and obesity, as well as preparing compounds for treatment of diabetes and obesity.Type: ApplicationFiled: March 14, 2008Publication date: December 9, 2010Applicant: Washington UniversityInventors: Jonathan B. Hurov, Helen Piwnica-Worms, Lewis C. Cantley
-
Patent number: 7846671Abstract: The present invention provides methods that are useful for the treatment or prevention of smooth muscle disorders such as urinary incontinence and compounds that are useful in such methods.Type: GrantFiled: January 27, 2003Date of Patent: December 7, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Mark Cockett, Chandra S. Ramanathan, Nicholas J. Lodge, Kevin Fitzgerald, Terry Stouch, Lisa Moore, Rachel M. Kindt, Jenny Kopczynski, Stephen Kohl Doberstein
-
Publication number: 20100305070Abstract: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.Type: ApplicationFiled: April 30, 2010Publication date: December 2, 2010Applicant: The University Court of the University of DundeeInventors: Steven Albert Everett, Saraj Ulhaq
-
Publication number: 20100304403Abstract: Luminescence assays and compositions for assay of biomolecular interaction and activity and detection of modulators of biomolecular interaction and activity are provided. Technology described herein has utility in a variety of assay formats and types, for example, simultaneous monitoring multiple parameters which affect interaction and activity of biological molecules. Compositions and methods are provided herein which include a first solid-phase support associated with a first specific binding agent and a photosensitizer; a second solid-phase support associated with a second specific binding agent and a first emission system; and a third solid-phase support associated with a third specific binding agent and a second emission system.Type: ApplicationFiled: February 22, 2010Publication date: December 2, 2010Inventors: Philippe Roby, Roger Bosse, Mathieu Arcand
-
Publication number: 20100303813Abstract: The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder.Type: ApplicationFiled: June 6, 2008Publication date: December 2, 2010Applicants: Biogen Idec MA Inc., The Feinstein Institute for Medical ResearchInventors: John P. Carulli, Peter K. Gregersen, Franak Batliwalla, Jadwiga Bienkowska, Chunyu Liu
-
Patent number: 7842513Abstract: This invention provides methods and compositions for testing for pregnancy and non-pregnancy in ungulates and non-hoofed ruminates. The tests provided by this invention are useful during a time that coincides with the estrus cycle during which breeding occurs or the first estrus cycle after breeding of a non-pregnant animal. The tests provided by this invention are useful in estrus and ovulation synchronization programs, with pregnancy testing useful at a time allowing for resynchronization of non-pregnant animals within the first estrus cycle. The tests provided by this invention assay for the presence, absence, or level of a selected IFN-?-induced protein in a sample from a female animal. The tests of this invention are useful for testing cells, blood, plasma, serum, cells, milk, nasal secretions, ocular secretions, vaginal secretions, urine, and saliva samples. The tests provided by this invention are immunoassays.Type: GrantFiled: May 2, 2003Date of Patent: November 30, 2010Assignees: AspenBio Pharma, Inc., University of WyomingInventors: Mark Colgin, Diane Newman, Cathy Landmann, Jay W. Roth, Roger Hurst, Thomas R. Hansen, Kathleen Jeanette Austin
-
Patent number: 7838246Abstract: The present invention provides biomarkers for schizophrenic and bipolar disorders and methods of diagnosis, monitoring and screening associated with the biomarkers and kits for performing such methods.Type: GrantFiled: February 14, 2006Date of Patent: November 23, 2010Assignee: Psynova Neurotech LimitedInventors: Sabine Bahn, Jeffrey Huang
-
Publication number: 20100291001Abstract: Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent metastatic disorders, hyperproliferative disorders, disorders which are characterized by excessive extracellular matrix degradation, and inflammatory disorders.Type: ApplicationFiled: December 19, 2008Publication date: November 18, 2010Applicant: DYAX CORP.Inventors: DANIEL T. DRANSFIELD, KRISTIN ROOKEY, ROBERT C. LADNER
-
Publication number: 20100284934Abstract: The invention provides an agent comprising an amino acid sequence for use in a method of diagnosis of a synucleinopathic disease.Type: ApplicationFiled: August 29, 2008Publication date: November 11, 2010Applicant: United Arab Emirates UniversityInventor: Omar El-Agnaf
-
Patent number: 7829289Abstract: The invention relates to methods of modulating an immune response in a mammal by modulating the activity of J?33 T cells or of MR1 polypeptide in vitro, ex vivo or in vivo. The invention also relates to methods of regulating the activity of immune cells, particularly of T lymphocytes and/or B lymphocytes by regulating the activity of MR1 in vitro, ex vivo or in vivo. The invention further comprises methods of screening active compounds using MR1 or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide. The invention also deals with a pharmaceutical composition comprising J?33 T cells, MR1 polypeptide or a compound that modulates the activity of J?33 TCR T cells or of MR1 polypeptide and a pharmaceutically acceptable vehicle or carrier. The invention further deals with methods of diagnosis for intestinal diseases related to a defect of the activity of said J?33 T cells or MR1 polypeptide.Type: GrantFiled: May 14, 2002Date of Patent: November 9, 2010Assignees: Institut National de la Sante et de Recherche Medicale, Institut CurieInventors: Olivier Lantz, Emmanuel Treiner
-
Publication number: 20100279314Abstract: The present invention relates to methods for detecting the activity of an ion channel in a cell. The methods comprise providing a loading buffer solution to a cell that has an ion channel. The loading buffer comprises at least one thallium indicator (e.g., an environmentally sensitive, luminescent dye) and a physiological concentration of chloride ions. The methods further comprise providing a stimulus buffer to the cell, wherein the stimulus buffer comprises thallium (e.g., thallium ions). Providing the stimulus buffer causes thallium influx into the cell through the ion channel. After providing the stimulus buffer, the luminescence (e.g., fluorescence) of the dye in the cell is detected. The luminescence of the dye can change in the presence or absence of thallium. The methods may be used to measure influx or efflux of thallium through an ion channel.Type: ApplicationFiled: October 15, 2008Publication date: November 4, 2010Inventors: Daniel Beacham, Kyle Gee
-
Publication number: 20100279891Abstract: This invention relates to methods for the evaluation and/or quantification of the binding affinity of small molecules or other compounds to target components contained within an analyte, such as target proteins contained within the proteome of a cell or tissue.Type: ApplicationFiled: September 26, 2008Publication date: November 4, 2010Inventors: Henrik Daub, Michaela Bairlein, Kirti Sharma, Klaus Godl, Andreas Tebbe, Christoph Weber
-
Patent number: 7824876Abstract: A bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), where free PAPP-A is determined either i) as a calculated difference between measured total PAPP-A and measured PAPP-A complexed to proMBP, or ii) by a direct bioaffinity assay measuring only free PAPP-A. Also disclosed is a method for diagnosing an acute coronary syndrome in a person by using as marker either free PAPP-A as such or a ratio free PAPP-A/total PAPP-A, free PAPP-A/PAPP-A complexed to proMBP, or PAPP-A complexed to proMBP/total PAPP-A.Type: GrantFiled: January 19, 2005Date of Patent: November 2, 2010Assignee: Turun YliopistoInventors: Qiu-Ping Qin, Kim Pettersson
-
Publication number: 20100273174Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.Type: ApplicationFiled: July 1, 2010Publication date: October 28, 2010Inventors: Arthur B. RAITANO, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
-
Publication number: 20100273188Abstract: The present invention relates to antibodies that have specificity towards prolactin binding protein (PRLBP) that is either bound to a binding partner or unbound to a binding partner, as well as antibodies towards PRLBP regardless of the binding state of PRLBP. The present invention also provides methods of using these PRLBP-specific antibodies, such as method of diagnosing and monitoring the progression of diseases such as epithelial carcinomas, osteoporosis, infertility and cachexia.Type: ApplicationFiled: February 26, 2010Publication date: October 28, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Charles CLEVENGER, William Sweet
-
Publication number: 20100273862Abstract: The present invention provides novel JNK activating phosphatase polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing JNK activating phosphatase polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with JNK activating phosphatase polypeptides.Type: ApplicationFiled: January 22, 2007Publication date: October 28, 2010Applicants: Amgen Inc., Baylor College of MedicineInventors: John W. Belmont, Frederick A. Fletcher, Alice J. Chen, Roland Jurecic, Tse-Hua Tan, Guisheng Zhou